secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001193125-26-109407
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics closes exclusive worldwide license for HCW11-006; receives $7M upfront fee
--------------------------------------------------------------------------------

- Total upfront fee of $7.0M: $3.5M cash plus $3.5M transferable equity interest in licensee Trimmune.
- HCW eligible for development milestones, double-digit royalties on future sales, and proceeds from future transactions.
- HCW has free option to recapture Americas rights after Phase 1 in China; Phase 1 expected H1 2027.
- Trimmune granted option to license HCW9302 for China; additional payments due if option exercised.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000119312526109407/0001193125-26-109407-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000119312526109407/hcwb-20260316.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-109407

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer